Sensitivity analysis for VE of the Pfizer-BioNTech COVID-19 vaccine against asymptomatic SARS-CoV-2 infection.

(DOCX)</p

S1 Fig -

Forest plots showing primary pooled vaccine effectiveness estimates and estimates from sensitivity analyses for (A) symptomatic PCR-confirmed COVID-19; (B) hospitalization due to COVID-19; (C) death due to COVID-19; and (D) asymptomatic SARS-CoV-2 infection. Pooled vaccine effectiveness estimates were derived from random effects meta-analyses (A-C) or fixed effects meta-analysis (D). (TIF)</p

Fig 3 -

Forest plots showing primary pooled vaccine effectiveness estimates and estimates from sensitivity analyses for (A) symptomatic PCR-confirmed COVID-19; (B) hospitalization due to COVID-19; (C) death due to COVID-19; and (D) asymptomatic SARS-CoV-2 infection. Pooled vaccine effectiveness estimates were derived from random effects meta-analyses (A-C) or fixed effects meta-analysis (D). Values for pooled effectiveness estimates and heterogeneity are shown in supplementary tables. 1Three studies provided a Delta-specific estimates [29, 31, 40] and one provided an estimate for the Delta-dominant period [33].</p

Evidence retrieval and article selection.

Evidence retrieval and article selection.</p

Sensitivity analysis for VE of the Pfizer-BioNTech COVID-19 vaccine against hospitalization due to COVID-19.

(DOCX)</p

PRISMA 2020 checklist.

(DOCX)</p

Sensitivity analysis for VE of the Pfizer-BioNTech COVID-19 vaccine against symptomatic laboratory-confirmed COVID-19.

(DOCX)</p

Sensitivity analysis for VE of the Pfizer-BioNTech COVID-19 vaccine against death due to COVID-19.

(DOCX)</p

Summary results from grading of recommendations, assessment, development and evaluation for Pfizer-BioNTech COVID-19 vaccine.

Summary results from grading of recommendations, assessment, development and evaluation for Pfizer-BioNTech COVID-19 vaccine.</p

Fig 2 -

Forest plots showing individual-study and pooled vaccine effectiveness estimates against (A) symptomatic PCR-confirmed COVID-19; (B) hospitalization due to COVID-19; (C) death due to COVID-19; and (D) asymptomatic SARS-CoV-2 infection. Pooled vaccine effectiveness estimates were derived from random effects meta-analyses (A-C) or fixed effects meta-analysis (D). Values for pooled effectiveness estimates and heterogeneity are shown in supplementary tables.</p